A Labelle

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. doi request reprint The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm
    Derek J Fisher
    Department of Psychology Institute of Neuroscience, Carleton University, Ottawa, Ont, Canada
    Clin Neurophysiol 119:909-21. 2008
  2. pmc Evidence review and clinical guidance for the use of ziprasidone in Canada
    David M Gardner
    Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    Ann Gen Psychiatry 12:1. 2013
  3. pmc Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia
    Sarojini Sengupta
    Department of Human Genetics, McGill University, Montreal, Canada
    BMC Genet 7:34. 2006
  4. ncbi request reprint Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia
    A Labelle
    University of Ottawa, Ontario
    Can J Psychiatry 44:887-92. 1999
  5. ncbi request reprint Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response
    A Labelle
    Schizophrenia Program, Royal Ottawa Hospital, Ottawa, Ontario
    Can J Psychiatry 46:534-41. 2001
  6. ncbi request reprint Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study
    Alain Labelle
    University of Ottawa, Psychology, Carleton University, Ottawa, Ontario, Canada
    J Clin Psychopharmacol 22:545-53. 2002
  7. ncbi request reprint Event-related potentials in schizophrenic patients during a degraded stimulus version of the visual continuous performance task
    V Knott
    Department of Psychiatry, University of Ottawa Royal Ottawa Hospital, Ontario, Canada
    Schizophr Res 35:263-78. 1999
  8. ncbi request reprint The treatment of negative symptoms: a clinical and methodological study
    Y D Lapierre
    Department of Psychiatry, Royal Ottawa Hospital, Ontario, Canada
    Int Clin Psychopharmacol 14:101-12. 1999
  9. ncbi request reprint Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment
    V Knott
    Department of Psychiatry and Psychology, University of Ottawa and Institute of Mental Health Research, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ont, Canada K1Z 7K4
    Schizophr Res 50:41-53. 2001
  10. ncbi request reprint Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia
    Donald Addington
    Departments of Psychiatry, University of Calgary, Calgary, Alberta, Canada
    J Clin Psychopharmacol 22:20-5. 2002

Collaborators

Detail Information

Publications19

  1. doi request reprint The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm
    Derek J Fisher
    Department of Psychology Institute of Neuroscience, Carleton University, Ottawa, Ont, Canada
    Clin Neurophysiol 119:909-21. 2008
    ..To examine pre-attentive acoustic change detection in schizophrenia patients with and without auditory hallucinations via mismatch negativity (MMN) extracted from a multi-feature paradigm...
  2. pmc Evidence review and clinical guidance for the use of ziprasidone in Canada
    David M Gardner
    Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
    Ann Gen Psychiatry 12:1. 2013
    ..Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success...
  3. pmc Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia
    Sarojini Sengupta
    Department of Human Genetics, McGill University, Montreal, Canada
    BMC Genet 7:34. 2006
    ....
  4. ncbi request reprint Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia
    A Labelle
    University of Ottawa, Ontario
    Can J Psychiatry 44:887-92. 1999
    ..To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control...
  5. ncbi request reprint Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response
    A Labelle
    Schizophrenia Program, Royal Ottawa Hospital, Ottawa, Ontario
    Can J Psychiatry 46:534-41. 2001
    ....
  6. ncbi request reprint Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study
    Alain Labelle
    University of Ottawa, Psychology, Carleton University, Ottawa, Ontario, Canada
    J Clin Psychopharmacol 22:545-53. 2002
    ..These results should be considered preliminary and require replication using appropriate control groups...
  7. ncbi request reprint Event-related potentials in schizophrenic patients during a degraded stimulus version of the visual continuous performance task
    V Knott
    Department of Psychiatry, University of Ottawa Royal Ottawa Hospital, Ontario, Canada
    Schizophr Res 35:263-78. 1999
    ..The implications of these findings are described in relation to attentional disturbances and trait versus state issues in schizophrenics...
  8. ncbi request reprint The treatment of negative symptoms: a clinical and methodological study
    Y D Lapierre
    Department of Psychiatry, Royal Ottawa Hospital, Ontario, Canada
    Int Clin Psychopharmacol 14:101-12. 1999
    ..In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia...
  9. ncbi request reprint Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment
    V Knott
    Department of Psychiatry and Psychology, University of Ottawa and Institute of Mental Health Research, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ont, Canada K1Z 7K4
    Schizophr Res 50:41-53. 2001
    ..The preliminary findings suggest that brain electric profiling may be a promising tool for assessing and understanding the central impact of pharmacotherapeutic interventions in schizophrenia...
  10. ncbi request reprint Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia
    Donald Addington
    Departments of Psychiatry, University of Calgary, Calgary, Alberta, Canada
    J Clin Psychopharmacol 22:20-5. 2002
    ..Testing the efficacy of widely accepted but poorly evaluated treatments should be a research priority. Future studies require a larger sample size and longer duration of treatment...
  11. ncbi request reprint Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia
    Hiroyuki Uchida
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Clin Psychiatry 69:1281-6. 2008
    ..The objective of this positron emission tomography (PET) study was to examine the striatal dopamine D(2) binding of long-acting risperidone administered intramuscularly once a month...
  12. ncbi request reprint Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol
    Luc J Boulay
    University of Ottawa Institute of Mental Health Research, Royal Ottawa Hospital Ottawa, Ontario Canada
    Cogn Neuropsychiatry 12:322-38. 2007
    ..To contrast the effect of a typical antipsychotic (haloperidol) and an atypical antipsychotic (olanzapine) on neurocognitive functioning in schizophrenia when learning and practice (LP) effects are controlled...
  13. ncbi request reprint A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 163:396-401. 2006
    ..The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks...
  14. ncbi request reprint Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients
    Ridha Joober
    Douglas Hospital Research Center, Douglas Hospital, Verdun, Quebec, Canada
    Schizophr Res 77:35-41. 2005
    ..In order to test this hypothesis, we compared the pattern of familial aggregation of schizophrenia related disorders in schizophrenic patients who are either responders (R) or nonresponders (NR) to typical neuroleptics...
  15. ncbi request reprint Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers
    Ridha Joober
    Douglas Hospital Research Center, McGill University, Que, H3A 1A1, Montreal, Canada
    Schizophr Res 53:229-38. 2002
    ....
  16. ncbi request reprint Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test
    Ridha Joober
    Arch Gen Psychiatry 59:662-3. 2002
  17. ncbi request reprint EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics
    Verner J Knott
    Department of Psychiatry and Psychology, University of Ottawa Royal Ottawa Hospital, Ontario, Canada
    Exp Clin Psychopharmacol 10:435-44. 2002
    ..Findings are discussed in relation to "disconnection" theories of schizophrenia...
  18. ncbi request reprint CAA insertion polymorphism in the 3'UTR of Nogo gene on 2p14 is not associated with schizophrenia
    Lan Xiong
    Department of Psychiatry, Douglas Hospital Research Centre, 6875 Boulevard LaSalle, FBC Pavillion, Verdun, Quebec, Canada H4H1R3
    Brain Res Mol Brain Res 133:153-6. 2005
    ..0% vs. 15.0%, chi2=0.985, p>0.1). Furthermore, neither CAAins/TATCdel individually, nor the haplotype carrying both CAAins and TATCdel is preferentially transmitted to affected offspring...
  19. ncbi request reprint Dopamine beta-hydroxylase (DBH) gene and schizophrenia phenotypic variability: a genetic association study
    Kenji Yamamoto
    Douglas Hospital Research Centre 6875 Boulevard LaSalle, Verdun H4H 1R3, Canada
    Am J Med Genet B Neuropsychiatr Genet 117:33-8. 2003
    ..These results suggest that the DBH gene is not a causative factor in schizophrenia but that it may be a modulator of psychotic symptoms, severity of the disorder and therapeutic response to neuroleptic drugs...